The SLE and LN market offers opportunities with the launch of 10 late-stage pipeline drugs improving safety and efficacy, contrasting with the current generic treatments. However, growth is challenged ...

Drug-induced lupus is more common in men because they are given these drugs more often; however, not everyone who takes these drugs will develop the disease. Specific criteria for diagnosing ...

Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight The SLE clinical trial analysis report delivers ...

Merck KGaA (Merck)’s investigational lupus therapy enpatoran will be advancing to Phase III trials after meeting the primary endpoint in one cohort but missing it in another. While the drug met the ...

William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s ...

In patients with systemic lupus erythematosus (SLE) who had been in remission for at least 1 year, immunosuppressant withdrawal was noninferior to glucocorticoid withdrawal, with no significant ...

Finally there's a bit of good news in the long search for a viable treatment. Lupus is an autoimmune disease in which the body's immune system attacks healthy, normal tissue. It mainly strikes women ...

“The European approval of Benlysta represents a significant milestone, and we are very pleased to be able to provide physicians an additional therapeutic option for treating appropriate patients with ...

Italian researchers reporting in the journal Cancers found a 32% increase in the odds for cancer in the first year after a ...